Eintrag weiter verarbeiten
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas
Gespeichert in:
| Zeitschriftentitel: | Antimicrobial Agents and Chemotherapy |
|---|---|
| Personen und Körperschaften: | , , , |
| In: | Antimicrobial Agents and Chemotherapy, 47, 2003, 1, S. 161-165 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society for Microbiology
|
| Schlagwörter: |
| author_facet |
Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. |
|---|---|
| author |
Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. |
| spellingShingle |
Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. Antimicrobial Agents and Chemotherapy In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas Infectious Diseases Pharmacology (medical) Pharmacology |
| author_sort |
waites, ken b. |
| spelling |
Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.47.1.161-165.2003 <jats:title>ABSTRACT</jats:title> <jats:p> The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 <jats:italic>Mycoplasma pneumoniae</jats:italic> , 45 <jats:italic>Mycoplasma hominis</jats:italic> , 15 <jats:italic>Mycoplasma fermentans</jats:italic> , and 68 <jats:italic>Ureaplasma</jats:italic> sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at ≤1 μg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC <jats:sub>90</jats:sub> s; ≤0.008 μg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for <jats:italic>M. pneumoniae</jats:italic> . For <jats:italic>M. hominis</jats:italic> , the garenoxacin MIC <jats:sub>90</jats:sub> (≤0.008 μg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 <jats:italic>M. fermentans</jats:italic> isolates were inhibited by garenoxacin at concentrations ≤0.008 μg/ml, making it the most active drug tested against this organism. For <jats:italic>Ureaplasma</jats:italic> spp., the garenoxacin MIC <jats:sub>90</jats:sub> (0.25 μg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against <jats:italic>M. pneumoniae</jats:italic> and <jats:italic>M. hominis</jats:italic> by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas. </jats:p> In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas Antimicrobial Agents and Chemotherapy |
| doi_str_mv |
10.1128/aac.47.1.161-165.2003 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDcuMS4xNjEtMTY1LjIwMDM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDcuMS4xNjEtMTY1LjIwMDM |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society for Microbiology, 2003 |
| imprint_str_mv |
American Society for Microbiology, 2003 |
| issn |
0066-4804 1098-6596 |
| issn_str_mv |
0066-4804 1098-6596 |
| language |
English |
| mega_collection |
American Society for Microbiology (CrossRef) |
| match_str |
waites2003invitrosusceptibilitiestoandbactericidalactivitiesofgarenoxacinbms284756andotherantimicrobialagentsagainsthumanmycoplasmasandureaplasmas |
| publishDateSort |
2003 |
| publisher |
American Society for Microbiology |
| recordtype |
ai |
| record_format |
ai |
| series |
Antimicrobial Agents and Chemotherapy |
| source_id |
49 |
| title |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_unstemmed |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_full |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_fullStr |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_full_unstemmed |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_short |
In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_sort |
in vitro susceptibilities to and bactericidal activities of garenoxacin (bms-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas |
| topic |
Infectious Diseases Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1128/aac.47.1.161-165.2003 |
| publishDate |
2003 |
| physical |
161-165 |
| description |
<jats:title>ABSTRACT</jats:title>
<jats:p>
The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63
<jats:italic>Mycoplasma pneumoniae</jats:italic>
, 45
<jats:italic>Mycoplasma hominis</jats:italic>
, 15
<jats:italic>Mycoplasma fermentans</jats:italic>
, and 68
<jats:italic>Ureaplasma</jats:italic>
sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at ≤1 μg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC
<jats:sub>90</jats:sub>
s; ≤0.008 μg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for
<jats:italic>M. pneumoniae</jats:italic>
. For
<jats:italic>M. hominis</jats:italic>
, the garenoxacin MIC
<jats:sub>90</jats:sub>
(≤0.008 μg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15
<jats:italic>M. fermentans</jats:italic>
isolates were inhibited by garenoxacin at concentrations ≤0.008 μg/ml, making it the most active drug tested against this organism. For
<jats:italic>Ureaplasma</jats:italic>
spp., the garenoxacin MIC
<jats:sub>90</jats:sub>
(0.25 μg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against
<jats:italic>M. pneumoniae</jats:italic>
and
<jats:italic>M. hominis</jats:italic>
by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.
</jats:p> |
| container_issue |
1 |
| container_start_page |
161 |
| container_title |
Antimicrobial Agents and Chemotherapy |
| container_volume |
47 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792343975261110277 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:00:14.697Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=In+Vitro+Susceptibilities+to+and+Bactericidal+Activities+of+Garenoxacin+%28BMS-284756%29+and+Other+Antimicrobial+Agents+against+Human+Mycoplasmas+and+Ureaplasmas&rft.date=2003-01-01&genre=article&issn=1098-6596&volume=47&issue=1&spage=161&epage=165&pages=161-165&jtitle=Antimicrobial+Agents+and+Chemotherapy&atitle=In+Vitro+Susceptibilities+to+and+Bactericidal+Activities+of+Garenoxacin+%28BMS-284756%29+and+Other+Antimicrobial+Agents+against+Human+Mycoplasmas+and+Ureaplasmas&aulast=Duffy&aufirst=Lynn+B.&rft_id=info%3Adoi%2F10.1128%2Faac.47.1.161-165.2003&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792343975261110277 |
| author | Waites, Ken B., Crabb, Donna M., Bing, Xue, Duffy, Lynn B. |
| author_facet | Waites, Ken B., Crabb, Donna M., Bing, Xue, Duffy, Lynn B., Waites, Ken B., Crabb, Donna M., Bing, Xue, Duffy, Lynn B. |
| author_sort | waites, ken b. |
| container_issue | 1 |
| container_start_page | 161 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 47 |
| description | <jats:title>ABSTRACT</jats:title> <jats:p> The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 <jats:italic>Mycoplasma pneumoniae</jats:italic> , 45 <jats:italic>Mycoplasma hominis</jats:italic> , 15 <jats:italic>Mycoplasma fermentans</jats:italic> , and 68 <jats:italic>Ureaplasma</jats:italic> sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at ≤1 μg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC <jats:sub>90</jats:sub> s; ≤0.008 μg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for <jats:italic>M. pneumoniae</jats:italic> . For <jats:italic>M. hominis</jats:italic> , the garenoxacin MIC <jats:sub>90</jats:sub> (≤0.008 μg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 <jats:italic>M. fermentans</jats:italic> isolates were inhibited by garenoxacin at concentrations ≤0.008 μg/ml, making it the most active drug tested against this organism. For <jats:italic>Ureaplasma</jats:italic> spp., the garenoxacin MIC <jats:sub>90</jats:sub> (0.25 μg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against <jats:italic>M. pneumoniae</jats:italic> and <jats:italic>M. hominis</jats:italic> by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas. </jats:p> |
| doi_str_mv | 10.1128/aac.47.1.161-165.2003 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuNDcuMS4xNjEtMTY1LjIwMDM |
| imprint | American Society for Microbiology, 2003 |
| imprint_str_mv | American Society for Microbiology, 2003 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0066-4804, 1098-6596 |
| issn_str_mv | 0066-4804, 1098-6596 |
| language | English |
| last_indexed | 2024-03-01T17:00:14.697Z |
| match_str | waites2003invitrosusceptibilitiestoandbactericidalactivitiesofgarenoxacinbms284756andotherantimicrobialagentsagainsthumanmycoplasmasandureaplasmas |
| mega_collection | American Society for Microbiology (CrossRef) |
| physical | 161-165 |
| publishDate | 2003 |
| publishDateSort | 2003 |
| publisher | American Society for Microbiology |
| record_format | ai |
| recordtype | ai |
| series | Antimicrobial Agents and Chemotherapy |
| source_id | 49 |
| spelling | Waites, Ken B. Crabb, Donna M. Bing, Xue Duffy, Lynn B. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.47.1.161-165.2003 <jats:title>ABSTRACT</jats:title> <jats:p> The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63 <jats:italic>Mycoplasma pneumoniae</jats:italic> , 45 <jats:italic>Mycoplasma hominis</jats:italic> , 15 <jats:italic>Mycoplasma fermentans</jats:italic> , and 68 <jats:italic>Ureaplasma</jats:italic> sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at ≤1 μg/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC <jats:sub>90</jats:sub> s; ≤0.008 μg/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for <jats:italic>M. pneumoniae</jats:italic> . For <jats:italic>M. hominis</jats:italic> , the garenoxacin MIC <jats:sub>90</jats:sub> (≤0.008 μg/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15 <jats:italic>M. fermentans</jats:italic> isolates were inhibited by garenoxacin at concentrations ≤0.008 μg/ml, making it the most active drug tested against this organism. For <jats:italic>Ureaplasma</jats:italic> spp., the garenoxacin MIC <jats:sub>90</jats:sub> (0.25 μg/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against <jats:italic>M. pneumoniae</jats:italic> and <jats:italic>M. hominis</jats:italic> by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas. </jats:p> In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas Antimicrobial Agents and Chemotherapy |
| spellingShingle | Waites, Ken B., Crabb, Donna M., Bing, Xue, Duffy, Lynn B., Antimicrobial Agents and Chemotherapy, In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas, Infectious Diseases, Pharmacology (medical), Pharmacology |
| title | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_full | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_fullStr | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_full_unstemmed | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_short | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| title_sort | in vitro susceptibilities to and bactericidal activities of garenoxacin (bms-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas |
| title_unstemmed | In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas |
| topic | Infectious Diseases, Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1128/aac.47.1.161-165.2003 |